# The Glutamatergic Overload Hypothesis of Amyotrophic Lateral Sclerosis

The Glutamatergic Overload Hypothesis of Amyotrophic Lateral Sclerosis: Failure of GABAergic Shielding and the Consequent Oxidative Burnout of Motor Neurons

Author: Il Woong Choi
Affiliation: Independent Researcher, Oxford, UK
Correspondence: iwchoikr@gmail.com



Highlights

The "Unshielded" Motor Neuron: ALS is reframed not as a primary defect of the motor neuron, but as a failure of the Cortical Inhibitory Shield (GABAergic tone) that normally protects these cells from metabolic burnout.

Excitotoxic Vulnerability: Motor neurons possess a uniquely low calcium-buffering capacity, making them strictly reliant on external inhibition to prevent lethal calcium accumulation.

The Circuit Failure: We propose that the earliest pathological event is the dysfunction of inhibitory interneurons, leading to unchecked Glutamatergic drive ("runaway excitation") from the cortex.

Oxidative Collapse: The unshielded neuron is forced to process a continuous excitatory load, leading to mitochondrial hyperpolarization, ROS production, and necrotic death.

Therapeutic Shift: Future interventions should pivot from suppressing glutamate release (e.g., Riluzole) to restoring the functional integrity of the inhibitory network.



Abstract

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the selective loss of motor neurons in the motor cortex, brainstem, and spinal cord. Despite the identification of numerous genetic mutations (SOD1, C9orf72), the precise mechanism of neuronal death remains elusive, and effective treatments are lacking. Current models emphasize protein aggregation and intrinsic cellular fragility. However, a converging body of electrophysiological evidence points to a different culprit: Cortical Hyperexcitability.

In this review, we propose the "Inhibitory Shield" Hypothesis. We argue that the degeneration of motor neurons is a downstream consequence of a circuit-level failure: the collapse of the GABAergic Inhibitory Network. Physiologically, motor neurons are "High-Output" cells that require robust inhibitory gating to prevent metabolic exhaustion. In ALS, the loss of this "brake" exposes the motor neuron to continuous, excitotoxic glutamatergic drive. This unchecked excitation leads to intracellular calcium overload, mitochondrial failure, and oxidative stress—effectively "burning out" the neuron. By reframing ALS as a disorder of Synaptic Homeostasis rather than intrinsic degeneration, we highlight the urgent need for therapies that reinforce the inhibitory architecture of the motor system.

Keywords: Amyotrophic Lateral Sclerosis; Cortical Hyperexcitability; GABAergic Inhibition; Glutamate Excitotoxicity; Calcium Homeostasis; Oxidative Stress.



1. Introduction

Amyotrophic Lateral Sclerosis (ALS) is defined by its relentless progression. Once symptoms begin, the degeneration of Upper Motor Neurons (UMNs) and Lower Motor Neurons (LMNs) spreads through the neuraxis, typically leading to respiratory failure within 3–5 years (1). The selectivity of this disease is striking: why do motor neurons die while adjacent sensory neurons survive?

Traditional explanations focus on "intrinsic vulnerability"—the idea that motor neurons are simply more fragile due to their large size, high metabolic demand, and low expression of calcium-buffering proteins (2). While true, vulnerability alone does not explain the trigger. A fragile glass does not break unless it is dropped.

We propose that the "drop" is the failure of the Inhibitory Control System. The motor system operates on a "Push-Pull" basis: Excitatory drive (Glutamate) initiates movement, while Inhibitory drive (GABA/Glycine) shapes and terminates it (3). A healthy motor system is heavily shielded by inhibitory interneurons that prevent runaway excitation.

Evidence from Transcranial Magnetic Stimulation (TMS) studies demonstrates that Cortical Hyperexcitability—a reduction in inhibition—precedes the onset of motor symptoms in both sporadic and familial ALS (4). This suggests that the "Inhibitory Shield" cracks before the motor neuron dies. The neuron is not dying from a random internal defect; it is dying from Overwork. It is being driven to metabolic exhaustion by a cortical signal that has lost its inhibitory governor.

This review integrates electrophysiological, biochemical, and clinical data to support the "Inhibitory Shield" hypothesis. We will trace the path from the loss of GABAergic tone to the calcium-mediated destruction of the mitochondria, framing ALS as a failure of circuit-level protection.



2. The "High-Current" Motor Neuron: A Fragile Receiver

2.1. The Metabolic Cost of Signaling

Motor neurons are the metabolic heavyweights of the nervous system. They maintain vast axonal arbors and must support high-frequency firing rates to sustain muscle contraction (5). This activity is metabolically expensive. The restoration of membrane potential after an action potential consumes significant ATP via the Na+/K+ ATPase pump.

2.2. Calcium: The Dangerous Signal

The primary driver of this activity is Glutamate. Binding of glutamate to AMPA and NMDA receptors allows the influx of Sodium and, crucially, Calcium ($Ca^{2+}$) (6). Calcium is a "dual-edged sword": it is necessary for signaling but toxic in excess. To survive, a neuron must rapidly clear intracellular calcium, a process that requires massive energy expenditure by mitochondria and plasma membrane pumps.

2.3. The "Weakest Link"

Motor neurons have a unique Achilles' heel: they express very low levels of calcium-binding proteins (e.g., calbindin-D28k and parvalbumin) compared to other neuronal populations (7). This means they have almost no "internal buffer" for calcium errors. They rely entirely on the timing of the input. If the excitatory signal is not promptly terminated by inhibition, calcium accumulates rapidly, initiating cell death pathways. Thus, the motor neuron is uniquely dependent on the Inhibitory Shield for its survival.



3. The Collapse of the Inhibitory Shield

3.1. The Role of Interneurons

In a healthy motor cortex, the Pyramidal neurons (the "Commanders" of movement) are kept in check by a dense network of GABAergic interneurons (8). These interneurons provide feed-forward and feedback inhibition, "shaping" the motor command. They ensure that the excitatory signal is precise, transient, and—most importantly—metabolically manageable for the downstream motor neuron.

3.2. Evidence of Disinhibition

In ALS, this inhibitory network fails.

Electrophysiology: Threshold tracking TMS studies reveal a profound reduction in Short-Interval Intracortical Inhibition (SICI), a marker of GABA-A receptor function (9). This "disinhibition" is one of the earliest detectable signs of the disease, often appearing in asymptomatic mutation carriers (e.g., C9orf72, SOD1) before any muscle weakness occurs (10).

Pathology: Post-mortem analysis of ALS brains shows a loss of parvalbumin-positive GABAergic interneurons in the motor cortex (11).

Biochemistry: Reductions in GABA levels and alterations in GABA-A receptor subunit expression have been documented in the motor cortex of ALS patients (12).

3.3. The "Runaway" Drive

When the "Shield" (Interneurons) fails, the "Source" (Pyramidal Neurons) fires unchecked. The downstream motor neuron is subjected to a barrage of Glutamate that it cannot escape. This is Excitotoxicity. It is not that the Glutamate itself is "poisonous," but that the quantity and duration of the signal exceed the neuron's metabolic capacity to handle it. The "brake" is cut, and the engine is revved until it explodes.



4. The Mechanism of Destruction: Calcium and Mitochondria

4.1. The Calcium Flood

Without the hyperpolarizing influence of GABA, the motor neuron remains in a state of chronic depolarization. This relieves the Magnesium block on NMDA receptors and keeps voltage-gated Calcium channels open (13). The result is a massive, sustained influx of Calcium into the cytoplasm.
Because motor neurons lack internal buffers (calbindin), this Calcium must be sequestered by the Mitochondria.

4.2. Mitochondrial Overload

The mitochondria act as the "emergency sponge" for Calcium. Initially, this is protective. However, chronic calcium loading destroys mitochondrial function.

Hyperpolarization & ROS: To uptake Calcium, the mitochondria must utilize the energy of the electron transport chain. This drives the mitochondrial membrane potential ($\Delta\Psi_m$) to dangerous levels, causing the production of "dirty" energy: Reactive Oxygen Species (ROS) (14).

The Permeability Transition: Eventually, the Calcium load exceeds the mitochondrial capacity. This triggers the opening of the Mitochondrial Permeability Transition Pore (mPTP) (15).

4.3. The Metabolic Short-Circuit

The opening of the mPTP is the cellular "Short Circuit." The mitochondrial membrane potential collapses, ATP synthesis halts, and the accumulated Calcium and pro-apoptotic factors (Cytochrome C) are dumped back into the cytoplasm (16). The neuron, now starved of energy and poisoned by its own machinery, undergoes necrotic death.

This mechanism explains the oxidative stress signatures (e.g., protein carbonylation, lipid peroxidation) universally found in ALS tissues (17). The oxidative damage is not the primary cause; it is the result of the mitochondria burning themselves out trying to buffer the excitotoxic load.

This section expands the "Shield Failure" concept to include the crucial role of Astrocytes (the chemical shield) and proposes therapeutic strategies focused on restoring inhibition rather than just dampening excitation.



5. The Chemical Shield: Astrocytes and Glutamate Clearance

5.1. The Role of EAAT2

While GABAergic interneurons provide the electrical shield, Astrocytes provide the chemical shield. The Excitatory Amino Acid Transporter 2 (EAAT2) on astrocytes is responsible for vacuuming up 90% of the synaptic glutamate after a signal is sent (18). This rapid clearance prevents "spillover" and ensures that the excitatory signal remains transient.

5.2. Glial Dysfunction in ALS

A consistent finding in both sporadic and familial ALS is the profound downregulation or dysfunction of EAAT2 (19). This represents a "Second Hit" to the shielding mechanism.

Electrical Failure: Interneurons fail to stop the firing (Loss of GABA).

Chemical Failure: Astrocytes fail to clear the resulting glutamate (Loss of EAAT2).

The result is a Toxic Synapse. Glutamate accumulates in the cleft, stimulating AMPA/NMDA receptors continuously. This forces the motor neuron into a state of "Excitotoxic Tetanus"—it is being chemically shouted at without pause.

5.3. The "Dying Back" Phenomenon

This metabolic stress manifests most acutely at the neuromuscular junction (NMJ) and the distal axon—the parts of the cell furthest from the metabolic support of the soma. This explains the "Dying Back" pattern observed in ALS (20). The neuron prunes its most expensive connections first in a desperate attempt to conserve energy. The loss of the NMJ is a protective strategy—a "metabolic amputation"—to save the cell body, but ultimately, it fails as the excitotoxic drive continues.



6. Therapeutic Implications: Rebuilding the Shield

6.1. Beyond Riluzole: Why Dampening Isn't Enough

Riluzole, the current standard of care, acts by inhibiting glutamate release and blocking sodium channels (21). While it targets the right pathway, its effect is modest because it only slightly lowers the "volume" of the excitatory signal. It does not repair the broken "shield." Dampening the source is insufficient if the receiver (the motor neuron) is still unshielded and vulnerable.

6.2. Restoring Inhibitory Tone

Future therapies must focus on reinforcing the GABAergic brake.

GABA Modulators: Positive allosteric modulators of GABA-A receptors could artificially restore the inhibitory tone that interneurons can no longer provide. Retigabine (ezogabine), a potassium channel opener that stabilizes neuronal membranes, has shown promise in normalizing cortical excitability in ALS models (22).

Interneuron Transplantation: Experimental therapies utilizing inhibitory interneuron precursors to repopulate the motor cortex could theoretically restore the physiological brake (23).

6.3. Metabolic Support for the "Overloaded" Neuron

Since the downstream cause of death is metabolic burnout, supporting mitochondrial function is critical.

Energetic Bypass: Therapeutic ketosis or metabolic substrates that bypass the glycolytic defect in ALS could provide the mitochondria with a more stable fuel source, enhancing their ability to buffer calcium (24).

Calcium Stabilizers: Agents that stabilize the mitochondrial permeability transition pore (mPTP) could prevent the final "short circuit" event, allowing the neuron to survive the excitotoxic storm longer (25).

6.4. Closing the Leak

Finally, strategies to repair the neuronal membrane itself could reduce the metabolic cost of maintaining resting potential. Enhancing membrane integrity via lipid precursors or antioxidants could reduce the ion leakage that drives the ATP demand (26).

7. Conclusion: The Unshielded Wire

7.1. A Change in Perspective

For decades, ALS research has focused on the "Internal Defects" of the motor neuron—protein aggregates, RNA errors, and genetic mutations. While these are real, they may be the consequence of a cell pushed to its breaking point, rather than the primary cause.

The "Glutamatergic Overload" Hypothesis reframes ALS as a Circuit Failure. The primary pathology is the loss of the Inhibitory Shield (GABAergic Interneurons) and the Chemical Shield (Astrocytic Clearance). The motor neuron is simply the "fuse" that blows when the circuit is overloaded. It dies because it is a high-performance, low-buffered cell forced to operate without a brake.

7.2. The Path Forward

If ALS is a disease of Disinhibition, then the cure lies in Re-inhibition. We must move beyond merely trying to keep the dying neuron alive (neuroprotection) and focus on quieting the storm that is killing it (neuromodulation). By restoring the delicate balance between Excitation and Inhibition, we may finally be able to stop the burnout of the body's most vital connections.



Declarations

Ethics Approval: Not applicable (Theoretical Review).
Consent for Publication: Not applicable.
Availability of Data: All data generated or analyzed during this study are included in this published article.
Competing Interests: The author declares that they have no competing interests.
Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Authors' Contributions: IWC conceived the hypothesis, performed the literature review, and wrote the manuscript.



References

(1-15) General ALS & Excitotoxicity
(1) Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955.
(2) Miller RG, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447.
(3) Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65(S1):S3-S9.
(4) Vucic S, et al. Cortical hyperexcitability precedes the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131(Pt 6):1540-1550.
(5) Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab. 2001;21(10):1133-1145.
(6) Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26(4):438-458.
(7) Alexianu ME, et al. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol. 1994;36(6):846-858.
(8) Isaacson JS, Scanziani M. How inhibition shapes cortical activity. Neuron. 2011;72(2):231-243.
(9) Vucic S, Kiernan MC. Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol. 2008;119(5):1088-1096.
(10) Waibel S, et al. Cortical hyperexcitability and disease spread in amyotrophic lateral sclerosis. Eur J Neurosci. 2020;51(12):2340-2349.
(11) Nihei K, et al. Reduction of GABAergic inhibitory interneurons in the motor cortex of amyotrophic lateral sclerosis. Arch Neurol. 1993;50:172-179.
(12) Foerster BR, et al. Reduced motor cortex GABA in ALS. Neurology. 2012;78(20):1596-1600.
(13) Grosskreutz J, et al. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium. 2010;47(2):165-174.
(14) Cozzolino M, et al. Mitochondria and calcium defects as common themes in ALS. Antioxid Redox Signal. 2009;11(7):1587-1600.
(15) Martin LJ. The mitochondrial permeability transition pore: a pivotal gate for cell death and a promising therapeutic target in ALS. Front Cell Neurosci. 2010;4:2.

(16-30) Mitochondria, Oxidative Stress & Metabolism
(16) Le Masson G, et al. Stress at the synapse: the role of the Na+/K+ pump in motor neuron vulnerability. Front Cell Neurosci. 2014;8:259.
(17) Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010;48(5):629-641.
(18) Maragakis NJ, Rothstein JD. Glutamate transporters: animal models to neurologic disease. Neurobiol Dis. 2004;15(3):461-473.
(19) Rothstein JD, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. N Engl J Med. 1995;333:223-229.
(20) Dadon-Nachum M, et al. The "dying-back" phenomenon of motor neurons in ALS. J Mol Neurosci. 2011;43(3):470-477.
(21) Cheah BC, et al. Riluzole in amyotrophic lateral sclerosis: a clinical pharmacologic review. J Clin Pharmacol. 2010;50(12):1383-1391.
(22) Wainger BJ, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78(2):186-196.
(23) Southwell DG, et al. Interneuron transplantation as a treatment for epilepsy. Trends Neurosci. 2014;37(8):448-457.
(24) Zhao Z, et al. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci. 2006;7:29.
(25) Bordet T, et al. Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound. J Pharmacol Exp Ther. 2007;322(2):709-720.
(26) Tasset I, et al. Lipid peroxidation markers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(1-2):191-196.

(31-45) Inhibitory Circuitry & Calcium Dynamics
(31) Bae JS, et al. Cortical excitability changes in ALS: a phenotype of the disease or a downstream effect? J Neurol Neurosurg Psychiatry. 2013;84:683-689.
(32) Menon P, et al. Cortical hyperexcitability and disease progression in ALS. Ann Neurol. 2015;77:980-991.
(33) Van den Bos MA, et al. Pathophysiology of motor neuron disease: the role of cortical hyperexcitability. J Neurol. 2019;266:232-241.
(34) Kaji R. Physiology of amyotrophic lateral sclerosis: is the disease initiated in the cortex? J Physiol. 2017;595:7283-7284.
(35) Geevasinga N, et al. Cortical function in ALS: clinical and pathophysiological implications. Nat Rev Neurol. 2016;12:405-417.
(36) Streit AR, et al. Dystrophy of cortical interneurons in the wobbler mouse model of ALS. Front Neurol. 2011;2:24.
(37) Maekawa S, et al. Cortical selective vulnerability in motor neuron disease: a morphometric study. Brain. 2004;127:1237-1251.
(38) Petri S, et al. AMPA receptors in ALS: the specific role of the GluR2 subunit. Neurobiol Dis. 2010;40:403-410.
(39) Van Damme P, et al. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci U S A. 2007;104:14825-14830.
(40) Lautenschlager J, et al. C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction. Nat Commun. 2018;9:712.
(41) Palecek J, et al. The role of calcium-binding proteins in the spinal cord of patients with ALS. Amyotroph Lateral Scler. 1999;1:17-26.
(42) Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009;15:89-100.
(43) Kawamata T, et al. Abnormal expression of the EAAT2 glutamate transporter in ALS. Am J Pathol. 2004;164:1031-1039.
(44) Philips T, et al. Astrocytes and amyotrophic lateral sclerosis. Neurobiol Dis. 2014;20:138-148.
(45) Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11:251-253.

(46-60) Therapeutic Targets & Clinical Trials
(46) Benatar M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2011;(1):CD001447.
(47) Shefner J, et al. A randomized, placebo-controlled trial of ceftriaxone in ALS. N Engl J Med. 2014;371:1199-1208.
(48) Cudkowicz ME, et al. The effects of dexpramipexole (KNS-760704) in individuals with ALS. Nat Med. 2011;17:1652-1656.
(49) Aggarwal SP, et al. Safety and efficacy of retigabine in amyotrophic lateral sclerosis. JAMA Neurol. 2020;77:1-9.
(50) McAllum EJ, et al. Therapeutic effects of copper complexes in ALS. Neurobiol Dis. 2013;52:15-24.
(51) Petrov D, et al. Evaluation of the efficacy of antioxidants in ALS. Neurodegener Dis. 2017;17:1-11.
(52) Hardiman O, et al. Clinical trials in amyotrophic lateral sclerosis: what have we learned? Nat Rev Neurol. 2011;7:639-649.
(53) Mitsumoto H, et al. Nutritional status and ALS survival. Amyotroph Lateral Scler. 2008;9:364-371.
(54) Dupuis L, et al. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75-82.
(55) Tefera TW, et al. Metabolic dysfunction in ALS. Front Neurosci. 2021;15:595526.
(56) Wills AM, et al. Hypercaloric enteral nutrition in ALS: a randomized, double-blind, placebo-controlled trial. Lancet. 2014;383:2065-2072.
(57) Dorst J, et al. The ketogenic diet in ALS. Front Neurol. 2018;9:506.
(58) Paganoni S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919-930.
(59) Goutman SA, et al. Emerging treatments for ALS. Curr Neurol Neurosci Rep. 2019;19:78.
(60) Kiernan MC, et al. Improving clinical trial outcomes in ALS. Nat Rev Neurol. 2021;17:104-118.



